About: Cyproterone acetate

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cyproterone acetate Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. [Pubchem] (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B58A4-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Giorgi EP, Shirley IM, Grant JK, Stewart JC: Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate. Biochem J. 1973 Mar;132(3):465-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4125095 # Pham-Huu-Trung MT, de Smitter N, Bogyo A, Girard F: Effects of cyproterone acetate on adrenal steroidogenesis in vitro. Horm Res. 1984;20(2):108-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6237971 # Stadtler FA, Langner V: The effect of cyproterone and gonadotrophins on the adrenal gland of juvenile and adult rats. A morphological and morphometrical study. Pathol Res Pract. 1985 Mar;179(4-5):493-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4001026 # Honer C, Nam K, Fink C, Marshall P, Ksander G, Chatelain RE, Cornell W, Steele R, Schweitzer R, Schumacher C: Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol Pharmacol. 2003 May;63(5):1012-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12695529 # Holdaway IM, Croxson MS, Evans MC, France J, Sheehan A, Wilson T, Ibbertson HK: Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism. Acta Endocrinol (Copenh). 1983 Oct;104(2):222-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6227191 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively. (en)
http://linked.open...ugbank/indication	For the palliative treatment of patients with advanced prostatic carcinoma. (en)
sameAs	Cyproterone acetate
Title	Cyproterone acetate (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB04839/identifier/drugbank/DB04839 http://linked.opendata.cz/resource/drugbank/drug/DB04839/identifier/pharmgkb/PA10049 http://linked.opendata.cz/resource/drugbank/drug/DB04839/identifier/chebi/50743 http://linked.opendata.cz/resource/drugbank/drug/DB04839/identifier/wikipedia/Cyproterone_acetate
http://linked.open...mechanismOfAction	The direct antiandrogenic effect of cyproterone is blockage of the binding of dihydrotestosterone to the specific receptors in the prostatic carcinoma cell. In addition, cyproterone exerts a negative feed-back on the hypothalamo-pituitary axis, by inhibiting the secretion of luteinizing hormone resulting in diminished production of testicular testosterone. (en)
http://linked.open...outeOfElimination	It is excreted approximately 60% in the bile and 33% through the kidneys. (en)
http://linked.open.../drugbank/synonym	Cyproterone 17-O-acetate (en)
http://linked.open...k/foodInteraction	Avoid alcohol. (en) Take after a meal. (en)
http://linked.open.../drugbank/mixture	Diane-35
http://linked.open...ynthesisReference	Aranya Manosroi, "Synthesis of cyproterone acetate." U.S. Patent US20040024230, issued February 05, 2004. (en)
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B58A9-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B58AF-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B58AE-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B58AB-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B58AC-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B58AD-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B58A7-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B58A5-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B58A8-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B58A6-363D-11E5-9242-09173F13E4C5
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B58B5-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B58B6-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B58B0-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B58B1-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B58B3-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B58B2-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B58B4-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Completely absorbed following oral administration. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	427-51-0 (en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B58BB-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B58BD-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B58BE-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B58BF-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B58BA-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B58B9-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B58BC-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B58AA-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B58B7-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B58B8-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software